GlassScriptPhysician profile
Julie Edwards
NPI 1538828124
$2,033.48
in general payments reported to CMS, 2019-2025
22 companies · $549 in 2025
The $549 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $605 · 2024: $643 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.27 | 2022-2025 | |
| Boston Scientific Corporation | $215.29 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Tris Pharma INC | $151.22 | 2022-2024 | Dyanavel Xr |
| Novo Nordisk INC | $103.25 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Organon LLC | $99.06 | 2022-2025 | Nexplanon |
| Pfizer INC. | $91.52 | 2023-2025 | |
| Axsome Therapeutics, INC. | $71.84 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $61.27 | 2022-2024 | Spravato |
| Lilly USA, LLC | $42.77 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $31.50 | 2023 | Shingrix, Arexvy |
| Cardiac Dimensions, INC. | $27.79 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.09 | 2022 | |
| Hologic Sales and Service, LLC | $17.51 | 2023 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $16.92 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.77 | 2023 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $16.64 | 2025 | |
| Merck Sharp & Dohme LLC | $15.63 | 2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Inspire Medical Systems, INC. | $15.63 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.48 | 2025 | Caplyta |
| Gilead Sciences, INC. | $14.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.62 | 2023 | |
| Mayne Pharma Commercial LLC | $8.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.